Key Takeaways Growing adoption of genetic testing, payer acceptance, and expanded infusion networks are driving revenue growth, pricing power, and increased patient access to therapies. Pipeline expansion, external collaborations, and manufacturing scale are positioning the company for diversified growth, improved margins, and long-term earnings gains.Read more
Key Takeaways Regulatory scrutiny and operational delays threaten timely access, increase compliance costs, and could pressure margins despite a favorable innovation climate and growing patient base. Overreliance on key products, delayed capacity expansion, and high upfront investments heighten risks of market saturation, revenue concentration, and sustained operating losses.Read more
Key Takeaways Addressing operational delays and administrative complexities in gene therapy could enhance revenue by quickly converting demand into treated patients. Expanding into LGMD and siRNA platforms diversifies revenue, potentially boosting earnings and financial stability.Read more
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children’s Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
